Lilly Said to Near Deal for Psychedelic Drugmaker AtaiBeckley

Eli Lilly (LLY) is in advanced talks to acquire AtaiBeckley Inc., a psychedelic drugmaker, according to people familiar with the matter. The deal would mark a significant bet by one of the world's largest pharmaceutical companies on psychedelic medicine, a sector that has transitioned from fringe science to mainstream pharmaceutical interest.

AtaiBeckley has focused on developing psychedelic-based therapies for mental health conditions. Lilly's potential acquisition follows the company's recent success in obesity and diabetes treatments, and would expand its neuroscience portfolio into a novel therapeutic area. No deal terms or transaction value were disclosed in the initial report.

The move signals Lilly's willingness to deploy capital into emerging therapeutic categories as competition intensifies among major drugmakers for innovative pipelines. Large pharmaceutical companies have increasingly explored psychedelic compounds after clinical data showed promise in treating depression, PTSD, and other psychiatric disorders where traditional treatments have fallen short.